Overview

PD-L1 Imaging in Non Small Cell Lung Cancer' (PINNACLE)

Status:
Active, not recruiting
Trial end date:
2022-11-30
Target enrollment:
Participant gender:
Summary
In this feasibility study, a zirconium-89 (89Zr)-avelumab positron emission tomography (PET) scan will be performed in 37 patients prior to treatment with avelumab to: 1. assess the tumor and systemic tissue uptake 89Zr-avelumab 2. assess the potential to predict avelumab treatment response
Phase:
Phase 1
Details
Lead Sponsor:
Radboud University
Collaborators:
Merck KGaA
Merck KGaA, Darmstadt, Germany
Treatments:
Antibodies, Monoclonal
Avelumab